BR112023021140A2 - Cofármaco compreendendo uma fração de agonista muscarínico e uma fração de agonista alfa2 adrenérgico, ou um sal farmacêutico deste, composição farmacêutica e formulação farmacêutica - Google Patents

Cofármaco compreendendo uma fração de agonista muscarínico e uma fração de agonista alfa2 adrenérgico, ou um sal farmacêutico deste, composição farmacêutica e formulação farmacêutica

Info

Publication number
BR112023021140A2
BR112023021140A2 BR112023021140A BR112023021140A BR112023021140A2 BR 112023021140 A2 BR112023021140 A2 BR 112023021140A2 BR 112023021140 A BR112023021140 A BR 112023021140A BR 112023021140 A BR112023021140 A BR 112023021140A BR 112023021140 A2 BR112023021140 A2 BR 112023021140A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical
fraction
agonist
copharmaco
muscarinic
Prior art date
Application number
BR112023021140A
Other languages
English (en)
Inventor
Jinsong Ni
Rong Yang
Van Dinh
Ken Fang Wenkui
Original Assignee
Ads Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ads Therapeutics Llc filed Critical Ads Therapeutics Llc
Publication of BR112023021140A2 publication Critical patent/BR112023021140A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

cofármaco compreendendo uma fração de agonista muscarínico e uma fração de agonista alfa2 adrenérgico, ou um sal farmacêutico deste, composição farmacêutica e formulação farmacêutica. um cofármaco ou um sal farmacêutico deste inclui uma fração de agonista muscarínico e uma fração de agonista alfa2 adrenérgico. a fração de agonista muscarínico e a fração de agonista alfa2 adrenérgico são conectadas covalentemente por meio de um ligante, e a ligação inclui um ligação de éster, uma ligação de amida, uma ligação de carbamato, ou uma combinação destes.
BR112023021140A 2021-04-16 2022-03-31 Cofármaco compreendendo uma fração de agonista muscarínico e uma fração de agonista alfa2 adrenérgico, ou um sal farmacêutico deste, composição farmacêutica e formulação farmacêutica BR112023021140A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163176149P 2021-04-16 2021-04-16
US202163272134P 2021-10-26 2021-10-26
PCT/US2022/022835 WO2022221071A1 (en) 2021-04-16 2022-03-31 Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs

Publications (1)

Publication Number Publication Date
BR112023021140A2 true BR112023021140A2 (pt) 2023-12-12

Family

ID=83639682

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021140A BR112023021140A2 (pt) 2021-04-16 2022-03-31 Cofármaco compreendendo uma fração de agonista muscarínico e uma fração de agonista alfa2 adrenérgico, ou um sal farmacêutico deste, composição farmacêutica e formulação farmacêutica

Country Status (7)

Country Link
EP (1) EP4322943A1 (pt)
JP (1) JP2024514870A (pt)
KR (1) KR20230172529A (pt)
AU (1) AU2022258105A1 (pt)
BR (1) BR112023021140A2 (pt)
CA (1) CA3214876A1 (pt)
WO (1) WO2022221071A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
WO2009117042A1 (en) * 2008-03-21 2009-09-24 Adlyfe, Inc. Use of pyrene to carry non-peptide agents across the blood brain barrier
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions

Also Published As

Publication number Publication date
EP4322943A1 (en) 2024-02-21
JP2024514870A (ja) 2024-04-03
WO2022221071A1 (en) 2022-10-20
AU2022258105A1 (en) 2023-10-26
KR20230172529A (ko) 2023-12-22
CA3214876A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
Barman et al. Amino acid conjugated polymers: antibacterial agents effective against drug-resistant Acinetobacter baumannii with no detectable resistance
Nahrwold et al. Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis
Puthenveetil et al. Natural product splicing inhibitors: a new class of antibody–drug conjugate (ADC) payloads
Lajiness et al. Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activation
MA38289A1 (fr) Composition pharmaceutique à biodisponibilité ameliorée
US7176185B2 (en) Short peptide carrier system for cellular delivery of agent
US10350217B2 (en) Antifungal agents and uses thereof
MA35153B1 (fr) Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondants
Sharma et al. Discovery of a membrane-active, ring-modified histidine containing ultrashort amphiphilic peptide that exhibits potent inhibition of Cryptococcus neoformans
EA202091135A1 (ru) Гидрофильные линкеры для конъюгатов антитело-лекарственное средство
BRPI0316732B8 (pt) composto derivado de 3-aminopirrolidina e sua composição farmacêutica
Steinbuch et al. Increased degree of unsaturation in the lipid of antifungal cationic amphiphiles facilitates selective fungal cell disruption
Leitheiser et al. Solid-phase synthesis of bleomycin group antibiotics. Construction of a 108-member deglycobleomycin library
BR112022013255A2 (pt) Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo
BR112023021140A2 (pt) Cofármaco compreendendo uma fração de agonista muscarínico e uma fração de agonista alfa2 adrenérgico, ou um sal farmacêutico deste, composição farmacêutica e formulação farmacêutica
Sarkar et al. Alkyl-aryl-vancomycins: multimodal glycopeptides with weak dependence on the bacterial metabolic state
Tovillas et al. Tn antigen mimics by ring-opening of chiral cyclic sulfamidates with carbohydrate C1-S-and C1-O-nucleophiles
Chen et al. Enantioselective synthesis of the R-enantiomer of the feeding deterrent (S)-Ypaoamide
MiáJeon et al. Camptothecin delivery into hepatoma cell line by galactose-appended fluorescent drug delivery system
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
Mandler et al. Modifications in synthesis strategy improve the yield and efficacy of geldanamycin− herceptin immunoconjugates
DE60203491D1 (de) Shiga-Toxin-Untereinheit B als Vektor zur Diagnose von Tumoren und zur Arzneimittelverabreichung an GB3-exprimierenden Tumoren
Pettit et al. Antineoplastic agents. 605. isoquinstatins
Gutman et al. Discovery of dolastatinol: A synthetic analog of dolastatin 10 and low nanomolar inhibitor of tubulin polymerization
Liu et al. Investigation of the relative cellular permeability of DNA-binding pyrrole− imidazole polyamides